EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prospective Observational Pilot Study of Myo-inositol and D-chiro-inositol (Femsol) in Women with Polycystic Ovary Syndrome in Tobruk, Libya

Inas Yhea, Wardah naji, Sameerah abduljawad, Radia almutkhatri, Fayazah Mohammed, Sarah makhzoum, Bilqyas Ashour, Maqboulah amtoubil

Libyan Journal of Medical Research · 18.05.2026 · 20 (2) · 271-275

DOI: 10.54361/ljmr.20.2.44 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Libyan Journal of Medical Research, online erschienen am 18.05.2026. Verfasst von Inas Yhea und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by reproductive, hormonal, and metabolic dysfunction. Current treatments often show limited efficacy and may be associated with adverse effects Objective To evaluate the efficacy of Femsol in improving clinical symptoms, hormonal profiles, and metabolic parameters in women with PCOS Methods: “A prospective observational pilot study was conducted on 100 women diagnosed with PCOS. Pre- and post-treatment parameters were compared using paired statistical analyses, Pre- and post-treatment parameters were compared using paired statistical tests. Due to partial reliance on simulated data and absence of a control group, findings are considered exploratory.

Result

Femsol demonstrated consistent improvements across clinical and biochemical domains. Symptom reduction ranged from 67.6% to 70.0%. Significant reductions were observed in AMH (−39.7%), LH/FSH ratio (−36.5%), testosterone (−31.0%), and HOMA-IR (−30.0%). Approximately 70% of participants met treatment response criteria.

Conclusion

Femsol appears to be a promising “Femsol showed promising preliminary effects on clinical, hormonal, and metabolic parameters in women with PCOS. Further randomised controlled studies are required to confirm these findings as a therapeutic option for PCOS. However, randomised controlled trials are required to confirm these findings.

Zitieren

APA

Yhea, I., naji, W., abduljawad, S., almutkhatri, R., Mohammed, F., makhzoum, S., Ashour, B., & amtoubil, M. (2026). Prospective Observational Pilot Study of Myo-inositol and D-chiro-inositol (Femsol) in Women with Polycystic Ovary Syndrome in Tobruk, Libya. Libyan Journal of Medical Research, 20(2), 271-275. https://doi.org/10.54361/ljmr.20.2.44

Vancouver

Yhea I, naji W, abduljawad S, almutkhatri R, Mohammed F, makhzoum S, et al. Prospective Observational Pilot Study of Myo-inositol and D-chiro-inositol (Femsol) in Women with Polycystic Ovary Syndrome in Tobruk, Libya. Libyan Journal of Medical Research. 2026;20(2):271-275. doi:10.54361/ljmr.20.2.44

BibTeX
@article{Yhea2026,
  author = {Yhea, Inas and naji, Wardah and abduljawad, Sameerah and almutkhatri, Radia and Mohammed, Fayazah and makhzoum, Sarah and Ashour, Bilqyas and amtoubil, Maqboulah},
  title = {Prospective Observational Pilot Study of Myo-inositol and D-chiro-inositol (Femsol) in Women with Polycystic Ovary Syndrome in Tobruk, Libya},
  journal = {Libyan Journal of Medical Research},
  year = {2026},
  volume = {20},
  number = {2},
  pages = {271--275},
  doi = {10.54361/ljmr.20.2.44}
}
Kostenlos starten →